Market Cap 789.85M
Revenue (ttm) 53.88M
Net Income (ttm) -173.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -322.90%
Debt to Equity Ratio 0.03
Volume 2,869,600
Avg Vol 1,860,448
Day's Range N/A - N/A
Shares Out 86.80M
Stochastic %K 41%
Beta 0.32
Analysts Strong Sell
Price Target $27.00

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 500 8800
Address:
12730 High Bluff Drive, Suite 400, San Diego, United States
Olena
Olena Oct. 25 at 8:28 PM
$KURA it should move up towards fda in November. Hope to $16 before fda decision
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 25 at 12:28 PM
$KURA lol. I used some extra powder to make a quick $2300 on this weeks dip. Sure, ain’t much but the aggregate EOY pays for my lake house
1 · Reply
saddy12345
saddy12345 Oct. 25 at 9:53 AM
$KURA Kura Oncology CEO Troy Edward Wilson bought shares in September 2025, acquiring 50,000 shares for approximately $410,145. He also sold 36,615 shares in late September 2025 for about $327,418 to cover taxes, according to MarketBeat and Investing.com. September 2025 Purchase: Wilson bought 50,000 shares at a weighted average price of about $8.20 per share. September 2025 Sale: He sold 36,615 shares for approximately $327,418. Reason for Sale: The sale was to cover taxes on performance-based restricted stock units that had vested.
0 · Reply
Klemmer777
Klemmer777 Oct. 25 at 8:57 AM
$KURA Tell me your salty about selling early without saying you’re salty about selling early😂
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $KURA Current Share Price: $9.18 Contracts: $KURA April 17, 2026 $10 Calls Scale in: $2.80- $3.42 Scale out: $4.36-$5.60 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MikeJonesSwishaHouse
MikeJonesSwishaHouse Oct. 24 at 11:07 PM
$KURA what am I missing here? ~ 600m in cash. Why are they so undervalued?
0 · Reply
roquefort
roquefort Oct. 24 at 10:41 PM
$KURA Seems like a derisking event to me. Hoping for $15 in runup to PDUFA.
0 · Reply
JFais
JFais Oct. 24 at 9:54 PM
$SNDX- Don't want to be a single stock poster, but will share a few more nuggets from the call as people asking for it: ***Usual caveats (am a Wall Street Nobody), but think bears/skeptics are missing forest for the trees -ONLY menin inhibitor with positive pivotal data in children, allowing for indication to treat patients 1 year of age or older -NPM1m AML pivotal data surpasses that seen for any other menin inhibitor across multiple efficacy measures (pot shot at $KURA and big pharma behind them) including on ORR, transplant rate, CR/CRh and median OS among responders. Particularly notable is 47% ORR and 11% transplant rate following Revuforj treatment. -While CR/CRc is key regulatory measure, ORR is key from a clinical standpoint (higher ORR gives clinicians ability to get more patients to remission and the best chance of bringing their eligible patients to potentially curative stem cell transplant)
1 · Reply
ConfidencePotato
ConfidencePotato Oct. 24 at 9:36 PM
$KURA Cantor Fitzgerald raised their KURA approval probability from 45% to 75% following deal diligence, while industry benchmarks suggest Breakthrough Therapy Designation confers 60-70% baseline probability. The current consensus probability is 65-75%, factoring in SNDX’s validation of the menin inhibitor mechanism, NPM1-mutant AML as a viable indication, and acceptable risk-benefit profiles for this desperate patient population.
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 24 at 7:51 PM
$KURA $SNDX hmmmm... @dgbio
0 · Reply
Latest News on KURA
Kura Oncology to Participate in Upcoming Investor Conference

Sep 24, 2025, 7:30 AM EDT - 4 weeks ago

Kura Oncology to Participate in Upcoming Investor Conference


Kura Oncology, Inc. - Special Call

Sep 16, 2025, 10:53 PM EDT - 5 weeks ago

Kura Oncology, Inc. - Special Call


Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 10:46 PM EDT - 2 months ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript


Kura Oncology Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results


Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results


Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:48 PM EDT - 6 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript


Kura Oncology Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 6 months ago

Kura Oncology Reports First Quarter 2025 Financial Results


Kura Oncology to Report First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology to Report First Quarter 2025 Financial Results


Kura Oncology to Participate in Stifel Targeted Oncology Forum

Apr 1, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum


Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:46 AM EST - 8 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript


Kura Oncology Announces Senior Executive Promotions

Jan 6, 2025, 4:30 PM EST - 10 months ago

Kura Oncology Announces Senior Executive Promotions


Kura Oncology to Host Virtual Investor Event on December 9, 2024

Dec 2, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024


Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 5:54 AM EST - 1 year ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript


Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Third Quarter 2024 Financial Results


Olena
Olena Oct. 25 at 8:28 PM
$KURA it should move up towards fda in November. Hope to $16 before fda decision
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 25 at 12:28 PM
$KURA lol. I used some extra powder to make a quick $2300 on this weeks dip. Sure, ain’t much but the aggregate EOY pays for my lake house
1 · Reply
saddy12345
saddy12345 Oct. 25 at 9:53 AM
$KURA Kura Oncology CEO Troy Edward Wilson bought shares in September 2025, acquiring 50,000 shares for approximately $410,145. He also sold 36,615 shares in late September 2025 for about $327,418 to cover taxes, according to MarketBeat and Investing.com. September 2025 Purchase: Wilson bought 50,000 shares at a weighted average price of about $8.20 per share. September 2025 Sale: He sold 36,615 shares for approximately $327,418. Reason for Sale: The sale was to cover taxes on performance-based restricted stock units that had vested.
0 · Reply
Klemmer777
Klemmer777 Oct. 25 at 8:57 AM
$KURA Tell me your salty about selling early without saying you’re salty about selling early😂
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $KURA Current Share Price: $9.18 Contracts: $KURA April 17, 2026 $10 Calls Scale in: $2.80- $3.42 Scale out: $4.36-$5.60 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MikeJonesSwishaHouse
MikeJonesSwishaHouse Oct. 24 at 11:07 PM
$KURA what am I missing here? ~ 600m in cash. Why are they so undervalued?
0 · Reply
roquefort
roquefort Oct. 24 at 10:41 PM
$KURA Seems like a derisking event to me. Hoping for $15 in runup to PDUFA.
0 · Reply
JFais
JFais Oct. 24 at 9:54 PM
$SNDX- Don't want to be a single stock poster, but will share a few more nuggets from the call as people asking for it: ***Usual caveats (am a Wall Street Nobody), but think bears/skeptics are missing forest for the trees -ONLY menin inhibitor with positive pivotal data in children, allowing for indication to treat patients 1 year of age or older -NPM1m AML pivotal data surpasses that seen for any other menin inhibitor across multiple efficacy measures (pot shot at $KURA and big pharma behind them) including on ORR, transplant rate, CR/CRh and median OS among responders. Particularly notable is 47% ORR and 11% transplant rate following Revuforj treatment. -While CR/CRc is key regulatory measure, ORR is key from a clinical standpoint (higher ORR gives clinicians ability to get more patients to remission and the best chance of bringing their eligible patients to potentially curative stem cell transplant)
1 · Reply
ConfidencePotato
ConfidencePotato Oct. 24 at 9:36 PM
$KURA Cantor Fitzgerald raised their KURA approval probability from 45% to 75% following deal diligence, while industry benchmarks suggest Breakthrough Therapy Designation confers 60-70% baseline probability. The current consensus probability is 65-75%, factoring in SNDX’s validation of the menin inhibitor mechanism, NPM1-mutant AML as a viable indication, and acceptable risk-benefit profiles for this desperate patient population.
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 24 at 7:51 PM
$KURA $SNDX hmmmm... @dgbio
0 · Reply
JFais
JFais Oct. 24 at 7:50 PM
$KURA- keep in mind how this trades if there's a CMC-related CRL (one reason I took profits re r/r) Again, hopeful zifto gets approved as more options for patients= a Win (and I can revisit as a commercial-stage setup if "sell the news") Reminder CEO known for overpromising...
3 · Reply
PickleRick10
PickleRick10 Oct. 24 at 7:34 PM
$SNDX no one here actually listened to the investor call. Company said VERY LOW rate of adverse effects and high efficacy, proven safety profile, and BETTER data than $KURA but will need to wait and see what their data says apparently
1 · Reply
Olena
Olena Oct. 24 at 7:21 PM
$SNDX load more on $KURA now! Next in line
1 · Reply
Candycaneispeppermint
Candycaneispeppermint Oct. 24 at 7:12 PM
$KURA I bought in after sndx poor outcome and added more just now. Trial safety data just looks to clean. I am getting fomo but will pump the breaks and look for more entry over coming two weeks. I think this one is in a prime position.
0 · Reply
lowfloatscambuster
lowfloatscambuster Oct. 24 at 7:09 PM
$KURA Jury still out on $SNDX but the safety warning is nothing but positive for KURA given the better safety and tolerability profile.
0 · Reply
Gundragon
Gundragon Oct. 24 at 5:57 PM
$KURA doesnt look like its reacting too well..
2 · Reply
ConfidencePotato
ConfidencePotato Oct. 24 at 5:46 PM
$KURA When sndx HALT lifts, we’ll know: • If M&A → KURA becomes even stronger hold • If offering → No impact on KURA thesis • If mystery good news → Probably bullish for sector
1 · Reply
GSD78626
GSD78626 Oct. 24 at 5:32 PM
0 · Reply
JFais
JFais Oct. 24 at 5:31 PM
$SNDX (L) Last point: The fact that Revuforj was approved in patients 1 year and older really speaks to risk/benefit profile in the context of a devastating & rapidly progressing disease Even without frontline (assume big pharma $JNJ Kyowa/ $KURA et al beat them there) $1B + easily in r/r alone as treatment durations move up to 12 months + majority of docs use in maintenance setting post-transplant GLTA and have a great weekend
1 · Reply
blueb22
blueb22 Oct. 24 at 5:30 PM
$KURA - SNDX received approval. That means Kura will get Zufto approval for sure (100%) and one time. So all good. And de-risked completely
0 · Reply
ConfidencePotato
ConfidencePotato Oct. 24 at 5:25 PM
$KURA boom for the tech….. let’s see now if she reacts as expected.
0 · Reply
diegosan21
diegosan21 Oct. 24 at 5:24 PM
$SNDX let's see those gains $KURA
1 · Reply